1-4 of 4
Alejandro Navarro
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5837: Lurbinectedin-induced transcriptional reprogramming: A pathway to sensitise SCLC to immunotherapy

Free
Joan Salvador Russo-Cabrera, Santiago Ponce-Aix, Patricia Cozar, Alicia Luengo, Belén Revuelta, Laura García-Redondo, Alejandro Navarro, Reyes Bernabé, María Eugenia Olmedo, José Manuel Trigo, Jon Zugazagoitia, Luis Paz-Ares, Itziar Otano
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 5837.
https://doi.org/10.1158/1538-7445.AM2025-5837
Published: 21 April 2025
View articletitled, Abstract 5837: Lurbinectedin-induced transcriptional reprogramming: A pathway to sensitise SCLC to immunotherapy
Journal Articles

Abstract CT253: Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)

Free
Delvys Rodríguez-Abreu, Maximillian Hochmair, Byoung Chul Cho, Tibor Csőszi, Talia Shentzer Kutiel, Veronika Müller, Myung-Ju Ahn, Dariusz Kowalski, Michele Maio, Vladimir Moiseyenko, Alejandro Navarro, Jianxin Niu, Andrea S. Fung, Carolin Lips, Heng Zhou, Bin Zhao, Humberto Lara-Guerra, Nir Peled
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT253.
https://doi.org/10.1158/1538-7445.AM2024-CT253
Published: 05 April 2024
View articletitled, Abstract CT253: Results from KEYNOTE-B99: Phase 2 study of first-line (1L) pembrolizumab (pembro) plus investigational agents and chemotherapy (chemo) for extensive-stage small-cell lung cancer (ES-SCLC)
Journal Articles

Abstract CT256: Results from KEYNOTE-B98: A phase 1b/2 study of pembrolizumab plus investigational agents in patients with anti-PD-(L)1-refractory extensive-stage small-cell lung cancer (ES-SCLC)

Free
Alejandro Navarro, Myung-Ju Ahn, James Stevenson, Nir Peled, Talia Shentzer Kutiel, Florian Huemer, Dong-Wan Kim, Maria Jove Casulleras, Adnan Khattak, Dariusz Kowalski, Natasha B. Leighl, Filippo de Marinis, Carolin Lips, Jiaxin Niu, Mo Huang, Bin Zhao, Hazem El-Osta, Taofeek Owonikoko
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT256.
https://doi.org/10.1158/1538-7445.AM2024-CT256
Published: 05 April 2024
View articletitled, Abstract CT256: Results from KEYNOTE-B98: A phase 1b/2 study of pembrolizumab plus investigational agents in patients with anti-PD-(L)1-refractory extensive-stage small-cell lung cancer (ES-SCLC)
Journal Articles

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

Free
Aleix Prat, Alejandro Navarro, Laia Paré, Noemí Reguart, Patricia Galván, Tomás Pascual, Alex Martínez, Paolo Nuciforo, Laura Comerma, Llucia Alos, Nuria Pardo, Susana Cedrés, Cheng Fan, Joel S. Parker, Lydia Gaba, Iván Victoria, Nuria Viñolas, Ana Vivancos, Ana Arance, Enriqueta Felip
Journal: Cancer Research
Cancer Res (2017) 77 (13): 3540–3550.
https://doi.org/10.1158/0008-5472.CAN-16-3556
Published: 02 July 2017
View articletitled, Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma
Open the PDF for Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma in another window
Includes: Supplementary data